Meet the Visionaries
Behind ReGENE

ReGENE was founded by a team of experts, including MIT alumni and UMass professors, who bring a wealth of knowledge and experience in biotechnology, evolutionary biology, and medicine.

Alexander
Suvorov

Founder & CEO

Dr. Suvorov is an Associate Professor at the University of Massachusetts Amherst. He has Sci. Dr. degree in evolutionary biology and expertise in molecular biology and toxicology developed through postdoctoral fellowships at Sherbrooke University (Canada) and Boston University. He has published more than 70 papers in peer-reviewed journals in the area of evolutionary biology, molecular toxicology, and biogerontology.

Mila Getmansky Sherman

Founder & Board of Directors Member

Dr. Getmansky Sherman is a Fuller and Meehan Endowed Professor of Finance at Isenberg School of Management, UMass Amherst. She conducted her PhD research at MIT and her current research interests include empirical asset pricing, systemic risk, hedge funds, financial crises, financial institutions, and system dynamics. She is an editor of the Journal of Alternative Investments and an associate editor of Data Science in Science.

Karl Ruping

Board of Directors Member

Dr. Ruping is the Managing Partner of incTANK Ventures, a team of experienced entrepreneurs investing in university-sourced startups. He founded or funded MIT-related startups including AgaMatrix (acquired by i-SENS Co.), Agrivida (acquired by Mitsui Co.), and Misfit Wearables (acquired by FOSSIL group). He is currently CEO of Tiba Biotech, an MIT venture focused on next-generation mRNA vaccines and therapeutics. Karl is a US patent attorney with a technical background in bioinformatics, molecular modeling.

Woody Sherman

ADVISER

Dr. Sherman conducted his PhD research in computational biochemistry at MIT. Currently he is CEO at Psivant Therapeutics. Prior roles included Chief Computational Scientist at Roivant Sciences, and Global Head of Applications Science at Schrodinger. He was a founding Chief Scientific Officer at Silicon Therapeutics acquired in 2021 by Roivant Sciences for $450 million.

Charles Joseph Eyermann

Senior Director, Computational Design

Dr. Eyermann is an experienced computational biochemist with 35+ years of drug discovery experience in pharmaceutical and biotech companies. He is an author of 60+ peer-reviewed publications and 10+ granted patents. His previous experience includes principal scientist positions at DuPont and DuPont Pharmaceuticals, AstraZeneca Pharmaceuticals R&D; and CEO at Boston Drug Design LLC.

Gregory S. Basarab

Consultant, drug discovery, medicinal chemistry, DMPK

Dr. Basarab conducted his PhD research in medicinal chemistry at MIT. He held leading positions in medicinal chemistry and pharmacology at AstraZeneca and DuPont. At Astra Zeneca he led Zoliflodacin project, currently in Phase 3. He is also a co-inventor of Durlobactam, for which NDA is currently under review at the FDA. As an independent consultant he works for a range of non-for-profit organizations and startups.

Ready to Revolutionize Aging? Reach Out to Us!

We’d love to hear from you! Whether you have questions, need more information, or want to explore potential collaborations, feel free to reach out to us through our contact form. Our team is ready to assist and provide the support you need.

Meet the Visionaries Behind ReGENE

Alexander Suvorov